Akebia, Keryx to merge, creating kidney disease specialist by Nick Paul Taylor Thursday, June 28, 2018 The combined company will own potentially complementary kidney disease drugs and a sales force to promote them.
Kadmon clinical POC data raise expectations for IPF drug by Nick Paul Taylor Tuesday, February 13, 2018 The ROCK2 inhibitor had a stronger effect on FVC than standard of care, but the lack of detail in the top-line data leave scope for doubts.
FibroGen soars as IPF data paint pamrevlumab as a blockbuster by Nick Paul Taylor Tuesday, August 8, 2017 Shares in the biotech shot up 60% after it posted phase 2 data that suggest it can muscle in on a market fought over by Boehringer and Roche.
Prolific dealmakers Akebia and Vifor pen anemia drug pact by Nick Paul Taylor Tuesday, May 16, 2017 Vifor Pharma has struck a deal to sell Akebia Therapeutics’ phase 3 oral anemia drug vadadustat through its network of U.S. dialysis centers.
Akebia, Otsuka pen $865M expansion to anemia pill pact by Nick Paul Taylor Wednesday, April 26, 2017 Otsuka Pharmaceutical has expanded its anemia pact with Akebia Therapeutics.
Phase 3 hit tees FibroGen, AstraZeneca up for anemia filing by Nick Paul Taylor Monday, January 30, 2017 FibroGen has posted positive phase 3 data on its AstraZeneca-partnered anemia drug.
FibroGen gains $62M collab payment from AstraZeneca on ‘blood doping’ pill by Ben Adams Friday, July 8, 2016 AstraZeneca has released $62 million for a license payment to partner FibroGen ($FGEN) as its experimental pill roxadustat continues its late-stage testing for anemia in kidney disease patients.
